DrugPatentWatch Database Preview
Enasidenib mesylate - Generic Drug Details
What are the generic drug sources for enasidenib mesylate and what is the scope of patent protection?
Enasidenib mesylate
is the generic ingredient in one branded drug marketed by Celgene Corp and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Enasidenib mesylate has seventy-two patent family members in thirty-four countries.
One supplier is listed for this compound.
Summary for enasidenib mesylate
| International Patents: | 72 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 47 |
| Clinical Trials: | 2 |
| Patent Applications: | 47 |
| DailyMed Link: | enasidenib mesylate at DailyMed |
Recent Clinical Trials for enasidenib mesylate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Jonsson Comprehensive Cancer Center | Phase 2 |
| M.D. Anderson Cancer Center | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
Pharmacology for enasidenib mesylate
| Drug Class | Isocitrate Dehydrogenase 2 Inhibitor |
| Mechanism of Action | Isocitrate Dehydrogenase 2 Inhibitors |
Synonyms for enasidenib mesylate
| 1446502-11-9 |
| 1650550-25-6 |
| 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol |
| 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol |
| 2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol |
| 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol |
| 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)- |
| 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, methanesulfonate (1:1) |
| 3T1SS4E7AG |
| 69Q |
| AG 221 |
| AG-221 |
| AG-221 (Enasidenib) |
| AG-221 mesylate |
| AG-221; Enasidenib |
| AG-221(Enasidenib) |
| AG221 |
| AKOS026750439 |
| BCP16041 |
| BCP26166 |
| CC 90007 |
| CC-90007 |
| CC-90007 Free Base |
| CC90007 |
| CHEMBL3989908 |
| CHEMBL3989931 |
| CS-5017 |
| CS-7541 |
| D10901 |
| D11044 |
| DB13874 |
| Enasidenib |
| Enasidenib (mesylate) |
| Enasidenib (USAN/INN) |
| Enasidenib [INN] |
| Enasidenib [USAN:INN] |
| Enasidenib mesilate |
| Enasidenib mesylate (USAN) |
| Enasidenib mesylate [USAN] |
| Enasidenib mesylate; AG-221 mesylate |
| Enasidenib methanesulfonate |
| EX-A1972 |
| EX-A654 |
| FT-0700204 |
| GTPL8960 |
| HY-18690 |
| HY-18690A |
| IDHIFA |
| Idhifa (TN) |
| J-690181 |
| KB-3356927 |
| KS-000006AW |
| NCGC00479249-03 |
| NCGC00479249-05 |
| s8205 |
| SB19193 |
| SCHEMBL15102202 |
| SCHEMBL16448052 |
| UF6PC17XAV |
| UNII-3T1SS4E7AG |
| UNII-UF6PC17XAV |
| ZINC222731806 |
US Patents and Regulatory Information for enasidenib mesylate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for enasidenib mesylate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201329054 | Start Trial |
| Peru | 20982014 | Start Trial |
| Israel | 233503 | Start Trial |
| Spain | 2675760 | Start Trial |
| Hungary | E038403 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.